On June 4, 2023, it was reported that First Trust Advisors LP had cut its holdings in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 8.4% in the fourth quarter. According to the company’s most recent Form 13F filing with the SEC, First Trust Advisors LP owned approximately 0.25% of Collegium Pharmaceutical worth $1,916,000 at the end of the reporting period.
Collegium Pharmaceutical is a pharmaceutical company that focuses on developing and commercializing abuse-deterrent products for patients suffering from chronic pain and other diseases. The company’s product portfolio includes Xtampza ER, Nucynta ER and Nucynta IR, Belbuca, and Symproic.
Despite the sell-off by First Trust Advisors LP, several equities analysts have recently issued positive reports on Collegium Pharmaceutical. Needham & Company LLC reiterated a “buy” rating and set a price target of $35.00 on shares of Collegium Pharmaceutical in April. StockNews.com also upgraded their rating from a “hold” to a “buy”. On Tuesday, April 25th, Piper Sandler reduced their target price on Collegium Pharmaceutical from $37.00 to $35.00.
The pharmaceutical industry is highly dynamic in nature with new developments emerging almost on a daily basis. The market for treatment options for patients suffering from chronic pain has been growing rapidly over time and Collegium Pharmaceuticals is well-positioned to tap this market opportunity.
It remains to be seen how First Trust Advisor’s decision to reduce its holdings in Collegium Pharmaceutical will affect future prospects for this pharmaceutical company as it continues its journey towards commercializing next-generation abuse-deterrent products for patients requiring treatment for chronic pain conditions and other diseases.
In conclusion, while First Trust Advisors has reduced its holdings in Collegium Pharmaceutical, several analysts remain bullish on potential future growth opportunities for this pharmaceutical company given the growing market for treatment options catering to patients suffering from chronic pain conditions and other ailments. It will be interesting to monitor how the company continues to evolve over time and manages to navigate through upcoming challenges while continuing its quest towards developing innovative healthcare solutions for patients in need.
[bs_slider_forecast ticker=”COLL”]
Investment Opportunities: Collegium Pharmaceutical Attracts Institutional Investors While Insiders Sell Shares
Collegium Pharmaceutical, Inc. is a pharmaceutical company dedicated to the development of abuse-deterrent products aimed at treating chronic pain and other illnesses. The company has caught the eye of investors worldwide with hedge funds and institutional investors making changes to their positions in COLL recently. Captrust Financial Advisors, PNC Financial Services Group Inc., U.S. Capital Wealth Advisors LLC, UBS Group AG, and Quantbot Technologies LP are among institutions that have either boosted their holdings (by up to 300%) or bought new positions.
Despite the increased interest shown by these institutions, some insiders have been selling their shares lately, including CEO Joseph Ciaffoni who sold 31,271 shares on May 30th for a total transaction of $684,834.90 according to an SEC filing. Colleen Tupper, the chief financial officer also sold 31,640 shares in March this year for a value of $752,082.80 while Joseph Ciaffoni made another sale of 31,271 shares earlier this year.
Shares of COL opened at $21.63 on June 4th with a market cap of $748.40 million resulting from a price-to-earnings-growth ratio at 0.23 while its P/E ratio stood at -25.15 indicating potential short-term investment opportunities despite missing Q1 earnings per share consensus estimates by ($0.02). Collegium Pharmaceutical’s product portfolio includes Xtampza ER which is designed for extended release pain relief; Nucynta ER and Nucynta IR used as pain medication boosters; Belbuca which assists in dealing with severe pain in varying dosages; and Symproic used in treating opioid-induced constipation.
Collegium Pharmaceutical’s low point over the last twelve months was recorded at $15.10 whereas its highest point was recorded at $30.22 pointing to potential profit margins if purchased at its low point. The company currently has a 1-year target price of $31 with analysts predicting a total year return of about 33.54%. With these statistics, Collegium Pharmaceutical presents an attractive investment opportunity that is bound to yield positive returns in the long run.
